Abstracts Archive - Page 1236 of 2425 - ACR Meeting Abstracts

Abstract Number: 457 • 2017 ACR/ARHP Annual Meeting
Levels of Satisfaction with RA Treatment and Associated Alignment between Rheumatologists and Their Patients across Latin America
Enrique R Soriano¹, José Antonio Maldonado-Cocco², David Vega-Morales³, Diana Rocio Gil⁴, Ivanio Pereira⁵, Generoso Guerra⁶, Wilson Bautista-Molano⁷, Julio Casasola⁸, Valderilio F Azevedo⁹, Leandro Aldunate¹⁰ and Steve Lobosco¹¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, CABA, Argentina, ²Buenos Aires University, Consulting Professor of Rheumatology, Buenos Aires University. Argentina, Buenos Aires, Argentina, ³Universidad Autónoma de Nuevo León. Rheumatology Service, Internal Medicine Department, Hospital Universitario "Dr. José Eleuterio González". Mexico, Monterrey, Mexico, ⁴ART Medica - Hospital Universitario Mayor MEDERI Internal Medicine and Rheumatology. Colombia., Bogota, Colombia, ⁵Rheumatology, Universidade Federal de Santa Catarina, Hospital Universitário, Divisão de Reumatologia.Brazil, Florianopolis, Brazil, ⁶Centro Médico Paitilla Internal Medicine and Rheumatology Department. Panama, Panama City, Panama, ⁷School of Medicine, Universidad Militar Nueva Granada and Rheumatology Department Hospital Militar. Colombia, Bogotá, Colombia, ⁸Rheumatology, Hospital General de Mexico, Mexico, Mexico, ⁹Adjunct Professor of Rheumatology, Federal University of Paraná; Brazil, Curitiba, Brazil, ¹⁰Immunology, Janssen Latin America, Buenos Aires, Argentina, ¹¹Adelphi, Immunology Director- Adelphi Group, Manchester, United Kingdom
Background/Purpose: To assess levels of rheumatologist and patient satisfaction with RA treatment across Latin America and any disconnects that may exist between the two in…
Abstract Number: 458 • 2017 ACR/ARHP Annual Meeting
Improving Knowledge of Rheumatoid Arthritis Clinical Trial Results Among Rheumatologists: Effect of an Online Educational Intervention
Edward Jackson and Piyali Chatterjee-Shin, Medscape Education, LLC, New York, NY
Background/Purpose: While major medical conferences provide the most up-to-date evidence regarding diseases and treatments, time demands and financial constraints are often cited as reasons for…
Abstract Number: 459 • 2017 ACR/ARHP Annual Meeting
Disease Course in Seronegative RA Patients Classified According to the 2010 ACR/EULAR Criteria
Lena Bugge Nordberg¹, Siri Lillegraven², Anna-Birgitte Aga², Inge C Olsen³, Elisabeth Lie⁴, Hilde B Hammer², Till Uhlig², Désirée van der Heijde⁵, Tore Kvien⁶ and Espen A. Haavardsholm², ¹Departement of Rheumatology, Diakonhjemmet hospital, oslo, Norway, ²Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁶Diakonhjemmet Hospital, Oslo, Norway
Background/Purpose: The development of the 2010 classification criteria for rheumatoid arthritis (RA) has led to a redefinition of the patient population, including classification of seropositive…
Abstract Number: 460 • 2017 ACR/ARHP Annual Meeting
Usefullness of Serum Angiogenic and Proinflammatory Cytokines to Discriminate between 6 Sets of Remission Criteria and Biomarkers of Radiographic Progression and Clinical Flare in RA in Clinical Remission. Pre-Eliminary Results of a Study of 5 Years of Follow-up
Julio Ramírez¹, Andrea Cuervo², Raquel Celis³, Virginia Ruiz-Esquide¹, M. Victoria Hernández⁴, Raimon Sanmarti⁵ and Juan D. Cañete⁶, ¹Rheumatology Service, Hospital Clínic de Barcelona, Barcelona, Spain, ²Arthritis Unit. Rheumatology Dpt, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ³Rheumatology, Arthritis Unit, Barcelona, Spain, ⁴Hospital Clinic. Barcelona. Spain, Barcelona, Spain, ⁵Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain, ⁶Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona, Barcelona, Spain
Background/Purpose: The primary aim of this study was to analyse serum levels differences of angiogenic and inflammatory biomarkers between SDAI, CDAI, ACR, DAS28 and sonographic…
Abstract Number: 461 • 2017 ACR/ARHP Annual Meeting
Additions to Methotrexate with Conventional and Biologic Dmards in Rheumatoid Arthritis: Are There Differences in Subsequent Time to Treatment Failure?
Sasha Bernatsky¹, Orit Schieir², Cristiano S. Moura³, Marie-France Valois⁴, Susan J. Bartlett⁵, Carol A Hitchon⁶, Janet E. Pope⁷, Gilles Boire⁸, Boulos Haraoui⁹, Edward C. Keystone¹⁰, Diane Tin¹¹, Carter Thorne¹² and Vivian P. Bykerk¹³, ¹Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²McGill University, Montreal, ON, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁸Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁹Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹⁰University of Toronto, Toronto, ON, Canada, ¹¹The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹²University of Toronto, Newmarket, ON, Canada, ¹³2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Our objective was to compare RA treatment strategies with conventional and biologic DMARDs after an initial MTX strategy was ineffective or associated with a…
Abstract Number: 462 • 2017 ACR/ARHP Annual Meeting
ABP 710: Matching Critical Biological Functions with Infliximab
Robert Sandrock¹, Palanisamy Kanakaraj² and Scott Kuhns¹, ¹Amgen, Inc., Thousand Oaks, CA, ²Amgen, Inc., Cambridge, MA
Background/Purpose: ABP 710 is being developed as a biosimilar to infliximab, a recombinant chimeric monoclonal antibody that binds tumor necrosis factor alpha (TNFa) and inhibits…
Abstract Number: 463 • 2017 ACR/ARHP Annual Meeting
Certolizumab Pegol for Fatigue in Chronic Inflammatory Rheumatic Diseases: A Meta-Analysis
Yesim Ozguler¹, Sinem Nihal Esatoglu¹, Guzin Karatemiz¹, Ali Ugur Unal², Gul Guzelant¹, Elif Dincses³, Mustafa Erdogan¹, Sema Kaymaz Tahra² and Gulen Hatemi¹, ¹Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Departement of Internal Medicine, Division of Rheumatology, Marmara University, Istanbul, Turkey, ³Istanbul University, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, İstanbul, Turkey
Background/Purpose: Fatigue is an important problem that impairs life quality in patients with rheumatic diseases. Although fatigue is often associated with disease activity, only a…
Abstract Number: 464 • 2017 ACR/ARHP Annual Meeting
Value of Matrix Metalloproteinase-3 Regarding Prediction for Joint Destruction at 1 Year Is Different between Sexes in Patients with Rheumatoid Arthritis
Yutaro Yamada¹, Kentaro Inui², Tadashi Okano³, Yuko Sugioka¹, Kenji Mamoto⁴, Kazuki Orita⁵, Tatsuya Koike⁶, Masahiro Tada⁷ and Hiroaki Nakamura³, ¹Orthopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ²Orhopedic surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ³Orthopaedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁴Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, ⁵Orthopedics, Shirahama hamayu Hospital, Shirahama, Japan, ⁶Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, ⁷Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan
Background/Purpose: Serum level of MMP-3 rises by synovial inflammation in patients with rheumatoid arthritis (RA). It destroys articular cartilage such as proteoglycans so that it…
Abstract Number: 465 • 2017 ACR/ARHP Annual Meeting
Basement Membrane Remodeling in Rheumatoid Arthritis Associates with Disease Activity, Response to IL-6 Inhibitor Treatment and Radiographic Progression: Analysis of Two Phase III Clinical Trials
Natasja Stæhr Gudman¹, Pernille Juhl¹, Christian S. Thudium², Peter Junker³, Anne Sofie Siebuhr⁴, Inger Byrjalsen¹, Morten Karsdal⁵ and Anne C. Bay-Jensen⁴, ¹Nordic Bioscience, Herlev, Denmark, ²Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ³Department of Rheumatology C, Odense University Hospital, Odense, Denmark, ⁴Rheumatology, Nordic Bioscience, Herlev, Denmark, ⁵Biomarkers and Reseacrh, Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) is associated with neovascularization of the synovial membrane and increased risk of cardiovascular co-morbidity. The extra cellular matrix below the endothelial…
Abstract Number: 466 • 2017 ACR/ARHP Annual Meeting
Plasma Cytokines at Diagnosis May Predict Non-Response to Methotrexate in Patients with Early Rheumatoid Arthritis
Martin Pelletier¹, Paul R. Fortin^1,2, Marie-Pier Longchamps¹, Geneviève Parent¹, Hadrien Benk-Fortin¹, Anne-Sophie Julien³, Nathalie Amiable¹, Emmanuelle Rollet-Labelle¹, Laetitia Michou², Louis Bessette² and Philippe A. Tessier¹, ¹Infectious Diseases and Immunity Research Division, CHU de Québec-Université Laval Research Center, Québec, QC, Canada, ²Division of Rheumatology, Department of Medicine, CHU de Québec-Université Laval, Québec, QC, Canada, ³Clinical Research Platform, CHU de Québec-Université Laval Research Center, Québec, QC, Canada
Background/Purpose: Methotrexate (MTX) is the first line treatment for patients with rheumatoid arthritis (RA). For over 30% of patients, MTX fails to diminish DAS28 score…
Abstract Number: 467 • 2017 ACR/ARHP Annual Meeting
Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid Arthritis
Angela Karellis^1,2, Emmanouil Rampakakis³, John S. Sampalis^1,4, Martin Cohen⁵, Michael Starr⁵, Peter Ste-Marie⁶, Yoram Shir⁶, Mark Ware⁶ and MaryAnn FitzCharles^6,7, ¹JSS Medical Research, St-Laurent, QC, Canada, ²Department of Surgery, McGill University, Montreal, QC, Canada, ³JSS Medical Research, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, ⁷Rheumatology, McGill University, Montreal, QC, Canada
Smoking and Opioid Use Is Associated with Symptom Severity in Rheumatoid ArthritisBackground/Purpose: Cigarette smoking, both current and past, is a risk for incident rheumatoid arthritis…
Abstract Number: 468 • 2017 ACR/ARHP Annual Meeting
Initiation of Biologic Disease Modifying Antirheumatic Drug Therapy and Associated Changes in Disease Activity Measures in Routine Clinical Practice: Findings from a Large Contemporaneous Real World Cohort
Zhaohui Su¹, Tom Brecht¹, Anna Lafontant¹, Costas Boussios¹, Francis O’Donovan², Charles Kekeh², Kathryn Starzyk¹, Richard Gliklich³ and Vandana Menon¹, ¹Research, OM1, Inc, Cambridge, MA, ²Data Science, OM1, Inc, Cambridge, MA, ³OM1, Inc, Cambridge, MA
Background/Purpose: While many clinical trials provide direct comparisons between biologic disease modifying antirheumatic drugs (bDMARD) and nonbiologic DMARD (nDMARD), there is a need for additional…
Abstract Number: 469 • 2017 ACR/ARHP Annual Meeting
Effect of Patient Involvement in Treatment Decision Making on Disease Outcomes in Rheumatoid Arthritis in the USA
Richard Hutchings¹, Shailja Panchal² and Elizabeth Baynton¹, ¹Ipsos Healthcare, London, United Kingdom, ²Ipsos Healthcare, New York, NY
Background/Purpose: ACR guidelines for treating Rheumatoid Arthritis (2015) suggest that treatment decisions should be made by physicians and patients through a shared decision-making process taking…
Abstract Number: 470 • 2017 ACR/ARHP Annual Meeting
Clinical Response to the First Biologic in Rheumatoid Arthritis Patients with Moderate Disease in a Real World Clinical Cohort
Xiuying Li, Angela Cesta, Mohammad Movahedi and Claire Bombardier, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada
Background/Purpose: While most randomized trials assess the effectiveness of biologic DMARDs (bDMARDs) in rheumatoid arthritis (RA) patients with high disease activity, in the real world…
Abstract Number: 471 • 2017 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Patients Resistant to Biologic Therapy, Are They Different?
Adeeba Al-Herz¹, Aqeel Ghanem², Khulood Saleh³, Adel Al-Awadhi⁴, Waleed Al-Kandari³, Eman Hasan⁵, Mohammad Hussain⁵, Ibrahim Nahar², Fatemah Abutiban⁶, Ahmad Alenizi⁶, Yaser Ali², Ali Aldei¹, Hebah Alhajeri², Sawsan Hayat², Ahmad Khadrawy³, Ammad Fazal³, Khaled Mokaddem¹, Agaz Zaman², Ghada Mazloum², Youssef Bartella¹, Sally Hamed¹, Ramia Alsouk⁶ and Ahmed Al-Saber⁷, ¹Rheumatology, Al-Amiri Hospital, Kuwait city, Kuwait, ²Rheumatology, Mubarak Al-Kabeer Hospital, Hawally, Kuwait, ³Rheumatology, Farwania Hospital, Farwania, Kuwait, ⁴Faculty of Medicine, Kuwait, Kuwait, ⁵Al-Amiri Hospital, Kuwait city, Kuwait, ⁶Rheumatology, Jahra Hospital, Jahra, Kuwait, ⁷Department of Mathematics, Kuwait Technical College, Kuwait city, Kuwait
Background/Purpose: Patients with rheumatoid arthritis (RA) may fail to respond to biologic therapy. We study patients who are resistant to different classes of biologic agents…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].